In this interview, Dr. Neil Sheppard, director of the Therapeutic Innovation in Natural Killer cells (THINK) lab at the ...

The main market opportunities lie in developing CD40-targeting therapies, including agonists for cancer immunotherapy and antagonists for autoimmune diseases. Innovations focus on overcoming systemic ...

B7-H4-targeted immunotherapies offer market opportunities in developing treatments for cancers with high B7-H4 expression, including ovarian, breast, and endometrial cancers. Utilizing diverse ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA ...

HHS Secretary Robert F. Kennedy Jr. claims that the aluminum ingredients in vaccines cause a variety of harmful reactions, ...

According to Mordor Intelligence, the cell therapy market is valued at USD 5.5 billion in 2025 and is projected to surpass ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

To celebrate a year in business, the owners of intravenous vitamin infusion business The Dripbar are offering free shots ...

Dual-target CAR-T cells attacking tumor cells and their matrix show strong efficacy in glioblastoma models, supporting ...

Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM ESTCompany ParticipantsSean McClain - Founder, CEO, ...

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.